Early aldosterone blocker for early stage PA
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests an early aldosterone blocker (eplerenone) in people with subtle primary aldosteronism (PA) to see if it prevents high blood pressure. You may qualify if you have slightly high aldosterone-to-renin ratio and no prior hypertension treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 30 and 55 years old.
- BMI between 18.5 and 35.
- Office blood pressure below 140/90 mmHg and no blood pressure medications ever.
- Blood tests showing a certain hormone pattern (high aldosterone to renin ratio or low renin).
- CT scan of adrenal glands showing small nodules or normal findings.
- No severe kidney, liver, or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for better ways to diagnose primary aldosteronism (PA), a common cause of high blood pressure that can be treated. It may help find people whose hypertension is caused by this condition so they can get the right treatment sooner.
This trial tests whether a new drug called SAL0140 can safely lower blood pressure in people with primary aldosteronism, a condition where the body makes too much of a hormone that raises blood pressure. You'll take the study drug at different dose levels while your blood pressure and kidney function are monitored.
This study looks at how primary aldosteronism affects the heart and blood vessels, and whether blocking its hormone signal (with spironolactone or eplerenone) changes those findings on imaging tests. It is small and focuses on people with confirmed or suspected primary aldosteronism who are being followed for heart health.
This study tests whether adjusting a type of blood pressure medication (called a mineralocorticoid receptor antagonist) based on renin levels is safe and helpful for people with primary aldosteronism. It aims to find a better way to manage the condition.
This trial tests whether a treatment called SAAE can improve “ventricular remodeling,” meaning changes in the heart muscle, in people with primary aldosteronism (PA). It may help the heart work more efficiently by targeting the cause of high aldosterone levels.
This trial tests a drug called finerenone for people with a specific cause of high blood pressure (primary aldosteronism). It aims to see if finerenone can help lower blood pressure and improve hormone levels better than current care.
Hear when a new Subclinical Primary Aldosteronism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.